Article
A novel retinoblastoma therapy from genomic and epigenetic analyses.
Nature - 11 Jan 2012
Zhang Jinghui, Benavente Claudia A, McEvoy Justina, Flores-Otero Jacqueline, Ding Li, Chen Xiang, Ulyanov Anatoly, Wu Gang, Wilson Matthew, Wang Jianmin, Brennan Rachel, Rusch Michael, Manning Amity L, Ma Jing, Easton John, Shurtleff Sheila, Mullighan Charles, Pounds Stanley, Mukatira Suraj, Gupta Pankaj, Neale Geoff, Zhao David, Lu Charles, Fulton Robert S, Fulton Lucinda L, Hong Xin, Dooling David J, Ochoa Kerri, Naeve Clayton, Dyson Nicholas J, Mardis Elaine R, Bahrami Armita, Ellison David, Wilson Richard K, Downing James R, Dyer Michael A
Abstract excerpt
Retinoblastoma is an aggressive childhood cancer of the developing retina that is initiated by the biallelic loss of RB1. Tumours progress very quickly following RB1 inactivation but the underlying mechanism is not known. Here we show that the retinoblastoma genome is stable, but that multiple cancer pathways can be epigenetically deregulated. To identify the mutations that cooperate with RB1 loss, we performed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.